PERSISTENT EFFECTS OF (+/-)3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA, ECSTASY) ON HUMAN SLEEP

被引:89
|
作者
ALLEN, RP
MCCANN, UD
RICAURTE, GA
机构
[1] NIMH, BIOL PSYCHIAT BRANCH, ANXIETY & AFFECT DISORDERS SECT, BLDG 10, BETHESDA, MD 20892 USA
[2] JOHNS HOPKINS UNIV, SCH MED, FRANCIS SCOTT KEY MED CTR, DEPT NEUROL, BALTIMORE, MD 21205 USA
来源
SLEEP | 1993年 / 16卷 / 06期
关键词
MDMA; SEROTONIN; NEUROTOXICITY; AMPHETAMINES; SLEEP;
D O I
10.1093/sleep/16.6.560
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
(+/-)3,4-methylenedioxymethamphetamine (MDMA) is a recreational drug of abuse which damages serotonin neurons in animals. It is not known whether MDMA is also neurotoxic in humans, and if so, whether there are functional consequences. Given the putative role of serotonin in sleep, it was hypothesized that one manifestation of serotonin neurotoxicity in humans might be disturbances of sleep. To determine whether MDMA use has effects on sleep, all-night polysomnograms of 23 MDMA users were compared to those of 22 age- and sex-matched controls. On average, MDMA users had 19 minutes less total sleep and 23.2 minutes less non-REM (NREM) sleep than controls. These statistically significant differences in NREM sleep were due primarily to an average of 37 minutes less stage 2 sleep, with no significant differences noted in stages 1, 3 or 4. Although it is not known whether the alterations in sleep observed in MDMA users are due to serotonin neurotoxicity, the present findings suggest that MDMA use can lead to persistent changes in CNS structures involved in human sleep generation.
引用
收藏
页码:560 / 564
页数:5
相关论文
共 50 条
  • [21] Sensitization to the prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA)
    Curry, Daniel W.
    Berro, Lais F.
    Belkoff, Andie R.
    Sulima, Agnieszka
    Rice, Kenner C.
    Howell, Leonard L.
    NEUROPHARMACOLOGY, 2019, 151 : 13 - 20
  • [22] Demographic and health characteristics of 3,4-methylenedioxymethamphetamine users (MDMA, ecstasy)
    Wieckiewicz, Gniewko
    Danel, Dariusz
    Piegza, Magdalena
    Gorczyca, Piotr
    Pudlo, Robert
    PSYCHIATRIA POLSKA, 2022, 56 (05) : 1109 - 1130
  • [23] Memory performance in abstinent 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") users
    Groth-Marnat, Gary
    Howchar, Hennedy
    Marsh, Ali
    PERCEPTUAL AND MOTOR SKILLS, 2007, 104 (01) : 43 - 55
  • [24] Toxicodynamics and long-term toxicity of the recreational drug, 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy')
    Ricaurte, GA
    McCann, UD
    Szabo, Z
    Scheffel, U
    TOXICOLOGY LETTERS, 2000, 112 : 143 - 146
  • [25] Acute Psychological Effects of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”) are Attenuated by the Serotonin Uptake Inhibitor Citalopram
    Matthias E Liechti
    Christine Baumann
    Alex Gamma
    Franz X Vollenweider
    Neuropsychopharmacology, 2000, 22 : 513 - 521
  • [26] Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") are attenuated by the serotonin uptake inhibitor citalopram
    Liechti, ME
    Baumann, C
    Gamma, A
    Vollenweider, FX
    NEUROPSYCHOPHARMACOLOGY, 2000, 22 (05) : 513 - 521
  • [27] Effects of (+)-fenfluramine on 3,4-methylenedioxymethamphetamine (MDMA) discrimination in rats
    Baker, LE
    Makhay, MM
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1996, 53 (02) : 455 - 461
  • [28] Cannabis and ecstasy/MDMA (3,4-methylenedioxymethamphetamine): an analysis of their neuropsychobiological interactions in recreational users
    Parrott, A. C.
    Milani, R. M.
    Gouzoulis-Mayfrank, E.
    Daumann, J.
    JOURNAL OF NEURAL TRANSMISSION, 2007, 114 (08) : 959 - 968
  • [29] 3,4-methylenedioxymethamphetamine (MDMA): current perspectives
    Meyer, Jerrold S.
    SUBSTANCE ABUSE AND REHABILITATION, 2013, 4 : 83 - 99
  • [30] 3,4-methylenedioxymethamphetamine (mdma): A review
    O’Leary G.
    Nargiso J.
    Weiss R.D.
    Current Psychiatry Reports, 2001, 3 (6) : 477 - 483